ZEVALIN, a radioactive monoclonal antibody from Biogen idec for non-Hodgkin's Lymphoma,
required specialized isolation rooms, intensive safety precautions, and radio-pharmacies for its administration.
These and other difficulties relegated it to "salvage therapy", the last treatment a physician would try after all others failed.
With solutions including TV, print advertising, and collateral to physicians and patients—as well as a novel Zevalin Concierge Support Program—this campaign helped make the entire process more accessible and understandable for oncologists, office staff, and patients.
required specialized isolation rooms, intensive safety precautions, and radio-pharmacies for its administration.
These and other difficulties relegated it to "salvage therapy", the last treatment a physician would try after all others failed.
With solutions including TV, print advertising, and collateral to physicians and patients—as well as a novel Zevalin Concierge Support Program—this campaign helped make the entire process more accessible and understandable for oncologists, office staff, and patients.
